Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country healthier and stronger."

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.

In a wide-ranging interview, Xavier Becerra, President Biden’s health secretary, defended his tenure and hinted that he might run for governor of California.

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for the 15 additional drugs, which will be handled by the incoming administration, assure major savings for Americans.

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of price negotiations, including the popular weight loss drugs Ozempic and Wegovy.

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

Xavier Becerra, the outgoing Health and Human ... Among the medications are popular weight loss treatments like Wegovy and Ozempic. "It will be left to the next administration to do the ...

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manuf

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year, with resulting bargained prices going into effect in 2027.